Economy

[EXPLAINER] Availability of HIV prevention pill in the Philippines

Prevention medicines for the human immunodeficiency virus (HIV) are available in the Philippines for at-risk populations, including men who have sex with men and sex workers, according to Manoj Sihag, Philippine country head of Camber Pharmaceuticals, Inc., a unit of Indian drugmaker Hetero Drugs.

In this explainer video, Mr. Sihag tells BusinessWorld reporter Patricia B. Mirasol how Filipinos can better prevent HIV infection.

He said Filipinos have low awareness about HIV, making them at risk of getting — and spreading — the disease.

“There are many patients who don’t know they are carrying HIV,” said Mr. Sihag.

The Health department has said 14,970 more Filipinos got HIV last year, 21% more than a year earlier. The increase pushed the average number of people diagnosed with HIV daily to 41 from 34.

There were about 140,000 HIV cases in the Philippines in 2021, according to the HIV and AIDS Data Hub website.

Read more: https://www.bworldonline.com/health/2023/03/29/513433/philippines-told-to-boost-awareness-about-hiv-aids/

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Most Popular

Your daily news source covering investing ideas, market stocks, business, retirement tips from Wall St. to Silicon Valley.

Disclaimer:

TheProficientInvestor.com, its managers, its employees, and assigns (collectively "The Company") do not make any guarantee or warranty about what is advertised above. Information provided by this website is for research purposes only and should not be considered as personalized financial advice.
The Company is not affiliated with, nor does it receive compensation from, any specific security. The Company is not registered or licensed by any governing body in any jurisdiction to give investing advice or provide investment recommendation. Any investments recommended here should be taken into consideration only after consulting with your investment advisor and after reviewing the prospectus or financial statements of the company.

Copyright © 2021 TheProficientInvestor. All Rights Reserved.

To Top